# Avalyn Pharma Inc.: financial statements, quarterly

AVLN · Nasdaq · CIK 1540171 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/avln.md) · [Financials](/companies/avln/financials.md) · [Filings](/companies/avln/filings.md) · [Insiders](/companies/avln/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/avln/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $m | [15.3](/filings/0001193125-26-254623.md) | [17.9](/filings/0001193125-26-345820.md) | [22.9](/filings/0001193125-26-254623.md) | [24.7](/filings/0001193125-26-345820.md) |
| Operating income | $m | [(18.7)](/filings/0001193125-26-254623.md) | [(21.8)](/filings/0001193125-26-345820.md) | [(27.9)](/filings/0001193125-26-254623.md) | [(31.3)](/filings/0001193125-26-345820.md) |
| Interest expense | $m | [0.0](/filings/0001193125-26-254623.md) | [0.0](/filings/0001193125-26-345820.md) | [0.1](/filings/0001193125-26-254623.md) | [0.3](/filings/0001193125-26-345820.md) |
| Income tax | $m | [0.0](/filings/0001193125-26-254623.md) | [0.0 d](/filings/0001193125-26-345820.md) | [0.0](/filings/0001193125-26-254623.md) | [0.0 d](/filings/0001193125-26-345820.md) |
| Net income | $m | [(17.5)](/filings/0001193125-26-345820.md) | [(20.2)](/filings/0001193125-26-345820.md) | [(26.9)](/filings/0001193125-26-345820.md) | [(28.9)](/filings/0001193125-26-345820.md) |
| Diluted EPS | $ per share | [(63.24)](/filings/0001193125-26-254623.md) | [(17.63)](/filings/0001193125-26-345820.md) | [(21.83)](/filings/0001193125-26-254623.md) | [(0.98)](/filings/0001193125-26-345820.md) |
| Basic EPS | $ per share | [(63.24)](/filings/0001193125-26-254623.md) | [(17.63)](/filings/0001193125-26-345820.md) | [(21.83)](/filings/0001193125-26-254623.md) | [(0.98)](/filings/0001193125-26-345820.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | [52.3](/filings/0001193125-26-345820.md) | [92.3](/filings/0001193125-26-254623.md) | [264](/filings/0001193125-26-345820.md) |
| Current assets | $m | not reported | not reported | not reported | [144](/filings/0001193125-26-345820.md) | [130](/filings/0001193125-26-254623.md) | [358](/filings/0001193125-26-345820.md) |
| Total assets | $m | not reported | not reported | not reported | [149](/filings/0001193125-26-345820.md) | [136](/filings/0001193125-26-254623.md) | [425](/filings/0001193125-26-345820.md) |
| Current liabilities | $m | not reported | not reported | not reported | [14.1](/filings/0001193125-26-345820.md) | [11.8](/filings/0001193125-26-254623.md) | [10.8](/filings/0001193125-26-345820.md) |
| Total liabilities | $m | not reported | not reported | not reported | [15.3](/filings/0001193125-26-345820.md) | [27.7](/filings/0001193125-26-254623.md) | [27.1](/filings/0001193125-26-345820.md) |
| Long-term debt | $m | not reported | not reported | not reported | [0.0](/filings/0001193125-26-345820.md) | [14.8](/filings/0001193125-26-254623.md) | [14.8](/filings/0001193125-26-345820.md) |
| Shareholders' equity | $m | [(175)](/filings/0001193125-26-345820.md) | [(192)](/filings/0001193125-26-345820.md) | [(194)](/filings/0001193125-26-345820.md) | [(239)](/filings/0001193125-26-345820.md) | [(264)](/filings/0001193125-26-345820.md) | [398](/filings/0001193125-26-345820.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(19.3)](/filings/0001193125-26-254623.md) | [(20.7) d](/filings/0001193125-26-345820.md) | [(29.9)](/filings/0001193125-26-254623.md) | [(26.1) d](/filings/0001193125-26-345820.md) |
| Capital expenditure | $m | [0.0](/filings/0001193125-26-254623.md) | [0.0 d](/filings/0001193125-26-345820.md) | [0.3](/filings/0001193125-26-254623.md) | [0.3 d](/filings/0001193125-26-345820.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.3](/filings/0001193125-26-254623.md) | [1.1](/filings/0001193125-26-345820.md) | [1.2](/filings/0001193125-26-254623.md) | [29.7](/filings/0001193125-26-345820.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 44,333,095 at 2026-08-31, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-345820.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.